Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

First-line chemo-free MCL combo is durable

Ruan J et al. Blood. 2018 Sep 4. doi: 10.1182/blood-2018-07-859769.

Key clinical point: Lenalidomide/rituximab induction and maintenance is an effective outpatient regimen for mantle cell lymphoma patients.

Major finding: After 64-months of median follow-up, 21 of 33 patients with initial responses remained in remission.

Study details: Five-year follow-up of a phase 2 single-arm trial of lenalidomide/rituximab induction and maintenance in 38 patients with mantle cell lymphoma.

Disclosures: The study was supported in part by Celgene Corporation, a Clinical Translational Science Center grant, and the Lymphoma Foundation. Dr. Ruan has received research support and been a consultant for Celgene, and other coauthors reported research support and consultant relationships with the company.

Read the article.

Citation:

Ruan J et al. Blood. 2018 Sep 4. doi : 10.1182/blood-2018-07-859769.

This Week's Must Reads

Guidelines for primary central nervous system lymphoma, Fox et al. Br J Haematol. 2018 Nov 23 doi: 10.1111/bjh.15661

FLYER evaluates number of R-CHOP cycles in DLBCL, Poeschel V et al. ASH 2018, Abstract 781

Ibrutinib-based therapy improves survival in CLL, Woyach JA et al. ASH 2018, Abstract 6

JULIET trial update on CAR T in DLBCL, Maziarz RT et al. N Engl J Med. 2018 Dec 1. doi: 10.1056/NEJMoa1804980

Long-term data on R-CHOP in follicular lymphoma, Wantanabe T et al. Lancet Haematol. 2018 Nov;5(11):e520-31

Must Reads in Aggressive Lymphomas

Guidelines for primary central nervous system lymphoma, Fox et al. Br J Haematol. 2018 Nov 23 doi: 10.1111/bjh.15661

FLYER evaluates number of R-CHOP cycles in DLBCL, Poeschel V et al. ASH 2018, Abstract 781

Ibrutinib-based therapy improves survival in CLL, Woyach JA et al. ASH 2018, Abstract 6

JULIET trial update on CAR T in DLBCL, Maziarz RT et al. N Engl J Med. 2018 Dec 1. doi: 10.1056/NEJMoa1804980

Patient perspectives on NHL treatment, Chircop D et al. Eur J Oncol Nurs. 2018 Aug;35:117-21